Carregant...
RDNA-10. HISTOPATHOLOGICAL AND GENOMIC CHARACTERIZATION OF GLIOBLASTOMA (GBM) RESECTED AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY
BACKGROUND: TTFields are FDA-approved for treatment of newly-diagnosed and recurrent glioblastoma. In this study, GBMs from one patient pre- and post-TTFields monotherapy were analyzed by immunohistochemistry (IHC) and array comparative genomic hybridization (aCGH) to examine potential TTFields-indu...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217519/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.925 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|